［1］ Xu Yuanqiu,Liu Siyuan,Zhang Weihua,et al.The molecular mechanism of the role of chemotherapeutic drugs for osteosarcoma and the choice of drug use methods［J］.Hebei Medicine,2015,37（14）:2100-2103.［徐袁秋，刘思源，张卫华， 等． 骨肉瘤常用化疗药物作用的分子机制及用药方法选择［J］． 河北医药，2015，37（14）:2100-2103．］
［2］ Huang Yongming,Huang Qiming,Xu Yisheng,et al.Preliminary study and prognostic analysis of vasculogenic mimicry in osteosarcoma［J］.Journal of Guangzhou University of Chinese Medicine,2013,30（2）:165-168.［黄永明，黄启明，徐逸生，等．骨肉瘤中血管生成拟态现象的初步研究和预后相关性分析［J］． 广州中医药大学学报，2013，30（2）:165-168．］
［3］Anderson ME．Update on survival in osteosarcoma［J］． Orthop Clin North Am，2016，47:283-292．
［4］Wu S，Cheng Z，Yu L，et al．Expression of CD82/KAI1 and HIF-la in non-small cell lung cancer and their relationship to vasculogenic mimicry［J］． Chinese Journal of Lung Cancer，2011，14:918-925．
［5］Isakoff MS，Bielack SS，Meltzer P，et al．Osteosarcoma:current treatment and a collaborative pathway to success［J］． J Clin Oncol，2015，33:3029-3035．
［6］Duong LM，Ｒichardson LC．Descriptive epidemiology of malignant primary osteosarcoma using population-based registries，United States，1999-2008［J］． J Ｒegistry Manag，2013，40:59-64．
［7］ Bajpai J，Sharma M，Sreenivas V，et al．VEGF expression as a prognostic marker in osteosarcoma［J］． Pediatr Blood Cancer，2018，53:1035-1039．
［8］Liu Yuanyuan，Wang Shengwei.Expressions and significance of VEGF and Ang-2 in serum of patients with NSCLC［J］.Modern Oncology,2015,23（19）:2774-2777.［刘源源，王生伟．非小细胞肺癌患者血清中VEGF和Ang-2的表达和临床意义［J］． 现代肿瘤医学，2015,23（19）:2774-2777．］
［9］Rigamonti N，Kadioglu E，Keklikoglou I，et al． Ｒole of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade［J］． Cell Ｒep，2014，8:696-706．
［10］ Bach F，Uddin FJ，Burke D． Angiopoietins inmalignancy［J］． Eur J Surg Oncol，2018，33:7-15．
［11］Moore DD，Luu HH． Osteosarcoma［J］． Cancer Treat Ｒes，2014，162:65-92．
［12］Yang J，Zhang W． New molecular insights into osteosarcoma targeted therapy［J］． Curr Opin Oncol，2013，25:398-406．
［13］ Hashizume H， Falcon BL， Kuroda T， et al． Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth［J］． Cancer Res，2010，70:2213-2313．
［14］Kienast Y， Klein C， Scheuer W， et al． Ang-2-VEGF-A Cross-Mab， anovel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously，mediates potent antitumor，antiangiogenic， and antimetastatic efficacy［J］． Clin Cancer Ｒes，2013，19:6730-6740．
［15］ Tsutsui S，Inoue H，Yasuda K，et al．Angiopoietin 2 expression in invasive ductal carcinoma of the breast:Its relationship to the VEGF expression and microvessel density［J］． Breast Cancer Ｒes Treat，2018，98:261-266．
［16］ Detjen KM，Ｒieke S，Deters A，et al． Angiopoietin-2 promotes disease progression of neuroendocrine tumors［J］． Clin Cancer Ｒes，2018，16:420-429．